Comparative Pharmacology
Head-to-head clinical analysis: GOCOVRI versus XENAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GOCOVRI versus XENAZINE.
GOCOVRI vs XENAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GOCOVRI (amantadine) is an NMDA receptor antagonist that modulates glutamate-mediated excitotoxicity and increases dopamine release by inhibiting the vesicular monoamine transporter 2 (VMAT2) and potentiating dopaminergic function. It also has anticholinergic properties.
Deutetrabenazine selectively and reversibly inhibits vesicular monoamine transporter 2 (VMAT2), thereby reducing dopamine and monoamine storage and release in presynaptic neurons.
Initial: 68.5 mg orally once daily at bedtime for 1 week; then increase to 137 mg once daily.
12.5 mg orally twice daily initially; titrate slowly by 12.5 mg every 3-5 days up to 50 mg twice daily (total daily dose 100 mg). Maximum recommended total daily dose: 100 mg.
None Documented
None Documented
The terminal elimination half-life is approximately 60–70 hours in healthy subjects, which supports once-daily dosing. Half-life may be prolonged in renal impairment.
7-16 hours (mean 9-12 hours); requires twice-daily dosing for steady-state control of chorea.
Renal excretion accounts for approximately 80% of elimination, with about 60% as unchanged drug and 20% as metabolites. Fecal excretion is minimal (<5%).
Primarily renal (75-85% as metabolites, <2% unchanged); minimal biliary/fecal elimination.
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor